Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Vitamin D Supplementation on Taxane-Induced Neuropathy
NCT05259527Phase 2Suspended
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2022
- Primary completion
- Mar 2030
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in neuropathic pain comparing Vitamin D Replacement, Standard of Care and Observation Arm (3 arms). Primary endpoints: Self-reported neuropathic pain- sensory symptoms at 12 weeks, Self-reported neuropathic pain- motor symptoms at 12 weeks and 1 more. Started Dec 2022; status: suspended.
02
Drugs
vitamin d
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT05259527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259527.